Adsorption of colicin B to a sensitive strain of Escherichia coli results in rapid cessation of deoxyribonucleic acid, ribonucleic acid, and protein synthesis. Some classes of mutants insensitive to colicin B hyperexcrete a colicin inhibitor into their growth medium. This inhibitor functions by preventing adsorption of colicin B and does not rescue cells to which colicin has already adsorbed. The inhibitor is insensitive to nucleases, proteolytic enzymes, and lysozyme and is not extracted into organic solvents. The inhibitory material has a low molecular weight, which rules out identification as lipopolysaccharide, although purified lipopolysaccharide has some inhibitory activity. Evidence is presented that the inhibitor is enterochelin, an iron chelator which is the cyclic trimer of 2,3-dihydroxybenzoylserine. Enterochelin does not inhibit colicin M, a colicin that is produced by many strains colicinogenic for colicin B.
Colicins were initially classified according to specificity of insensitive mutants (9) and the model of resistance due to receptor loss was originally applied to mutants insensitive to colicin B. Isolation of tolerant mutants, which adsorb one or more colicins but are not killed by them (16) , broadened the range of insensitivity mechanisms. The tolerance of Escherichia coli tol II mutants extends to colicins A, El, E2, E3, and K but not to colicins B, I and V. Gratia (11) described mutants insensitive to these colTins, but the mechanism of their insensitivity has remained obscure. In a search for mutants tolerant to colicin B, several mutants were found that were insensitive to colicins B, I, and sometimes also to V and which excreted a colicin inhibitor (13) . Further studies were directed to identification of the inhibitor and clarification of its mode of action and its role in the insensitivity of the excreting strains.
The data presented here indicate that the colicin B inhibitor is the iron chelating compound enterochelin (6) , also known as enterobactin (24) , the cyclic trimer of 2, 3-dihydroxybenzoylserine (DHBS: 18). Brot et al. (2) described an enzymatic activity in E. coli that synthesizes DHBS from serine, 2,3-dihydroxybenzoic acid (DHBA), and adenosine 5'-triphosphate. This activity is repressed by exoge-J. BACTERIOL. Na2SO4, and removed by flash evaporation, and the residue was dissolved in ethyl acetate and analyzed by two-dimensional chromatography. Prepared analytical plates (MN300 from Brinkman Co.) were washed in the first solvent (benzene: acetic acid: water, 125:72:3). Samples were chromatographed in this solvent; the plates were dried and chromatographed in the second dimension with 5% ammonium formate in 0.5% formic acid. The plates were examined for fluorescent spots with an ultraviolet lamp and sprayed with 1% FeSO4 for color development. The ability of material in various spots to inhibit colicin was tested by placing portions of the chromatogram on 2% nutrient agar, overlaying with 3 ml of 1% nutrient agar containing crude colicin, sealing with 3 ml of nutrient agar, sterilizing with CHClI vapor, and overlaying with 2.5 ml of soft agar seeded with indicator cells. Overnight incubation revealed inhibition of colicin killing by the presence of a patch of confluent growth.
RESULTS
Conditions for optimal colicin B killing. The presence of nutrient broth rather than phosphate buffer in assay mixtures enhanced the colicin B titer one and a half-to twofold. This effect may be similar to the stabilization of purified colicin E2 by bovine serum albumin (14) . Indicator cells grown in nutrient broth were three to four times more sensitive than the same strain grown in LB broth. An increase in colicin titer was produced by inclusion of MgCl2 with a maximum near 0.01 M. Most titrations of colicin B, therefore, were carried out with indicator cells grown in nutrient broth and in the presence of nutrient broth and 0.013 M MgCl2.
Action of colicin B on cellular biosyntheses. As shown in Fig. 1 , colicin B drastically reduces synthesis of DNA, RNA, and protein.
The residual incorporation is somewhat too large, however, to be ascribed to surviving cells. Colicin B did not cause acid solubilization of prelabeled DNA (data not shown). Thus, this colicin may have the same general mode of biochemical action as colicins A (15), El and K (7), and Ia and Ib (17) .
General properties of a colicin inhibitor. A colicin inhibitor produced by mutants insensitive to colicins B, Ia, and Ib protects sensitive cells from these colicins (12, 13) . These mutants are identified as exb strains. The inhibitor did not protect sensitive cells from colicins A, El, E2, E3, K, or V. Colicin was not progressively destroyed during a 2-h incubation period with the inhibitor since its residual activity remained constant. The activity was unaffected by 100 C for 1 min, dialysis into distilled water, Millipore filtration, exposure to nucleases, proteolytic enzymes, or lysozyme. The inhibitor was assumed to have a low molecular weight since it remained in solution after addition of trichloracetic acid, dialyzed into high ionic strength buffer, and was eluted from a Sephadex G25 column in fractions including and beyond those containing NaCl in the column calibration (S. K. Guterman, Ph.D. thesis).
Identification of the inhibitor with enterochelin. A variety of findings, some already reported (12) , corrobate the identity of the colicin B inhibitor with enterochelin. Purified -O 00 ,, "' 8 ZI?
a-4 C-, enterochelin exhibits strong inhibitory activity. Like enterochelin (18) , the inhibitor is quantitatively extracted from inhibitory supernatant fluids with ethyl acetate. In thin-layer chromatography these extracts reveal a fluorescent spot with the same R, in two solvent systems as authentic enterochelin. The material in that fluorescent spot was inhibitory for colicin B, whereas other fluorescent components of the extracts were not.
Mutants of Salmonella typhimurium LT 2 known as enb mutants are defective in production of enterobactin from chorismic acid (23) . Mutants blocked before production of DHBA produce enterobactin if DHBA is added to the medium. As shown in Table 2 , an enb mutant blocked in the synthesis of DHBA produced no inhibitor unless it was provided with DHBA, under which conditions it made a quantity of inhibitor comparable to that produced by the parent strain. A similar result was obtained with strain AN193, ent mutant of E. coli blocked in enterochelin synthesis (6) . The enb mutants are inhibited by 1 mM citrate; normal growth rate in the presence of citrate is restored by 1 gM enterobactin (23) . The substance present in the culture media of inhibitor-excreting strain GUC 12 also allowed the enb mutant GUS 7 to grow in the presence of citrate medium (Fig. 2) , while the parent C600 supernatant fluid similarly diluted did not.
Production of colicin inhibitor by wild-type strain C600 was strongly repressed by addition of 200 ,uM FeCl8 (12) , just as the production of enterochelin is known to be repressed (2, 4, 19, 32) . Mutants of the exb type produce pink supernatant fluids when grown in M9 medium supplemented with 100 ,M FeCl3. The parents yield colorless supernatant fluids. Absorption spectra shown in Fig. 3 Antagonism between an exb supernatant factor and citrate for growth inhibition of GUS 7 enb. A, LT 2 and GUS 7 (enb-7) cells were grown in A medium with or without 1 mM sodium citrate. B, GUS 7 cells were grown as above but with the addition of sterile 1:100 dilution of the supernatant factor of either C600 or GUC 12 exb to the medium. C600 and GUC exb had been grown in M9 medium with 100IAM FeCI3-243 and 311 nm (18) . In supernatant fluids of M9 cultures with 200 AM FeCls added, the catechol concentration was 5 ,M "2, 3-dihydroxybenzoic acid equivalents" for strain C600 and 100 ,uM for the exb mutant GUC 12.
All these data are consistent with identification of the hyperexcreted substance with a catechol, more specifically with enterochelin.
Enterochelin inhibits colicin B adsorption. To test whether the colicin B inhibitor acts on sensitive cells, E. coli GUA 1, an aroC strain that is colicin sensitive and produces no inhibitor (12) , was preincubated 30 To test if enterochelin could remove colicin B already adsorbed to cells, colicin was mixed with indicator cells, adsorption was stopped by a 1:100 dilution into medium, the cells were further diluted into either inhibitory supernatant fluid or control medium, and the survival was monitored. No rescue by inhibitor was observed (Fig. 4) .
Identification of the inhibitor as enterochelin raises the possibility that iron chelation may play a role in the inhibition. This hypothesis was tested by assaying colicin titer and inhibitory activity after colicin or inhibitor was preincubated with 100 ,uM FeCl3. The remaining components were then added, varying the order to include all possibilities. Incubation of colicin or inhibitor with iron affected neither colicin titer nor inhibitory activity (Table 3) , indicating that unavailability of iron is probably not the basis of colicin inhibition by enterochelin.
To test if the inhibitor functions by preventing the initial adsorption of colicin, a mixture of colicin and GUA 1 cells was incubated in the presence of inhibitor. The cells were removed from the mixture, the supernatant fluid was dialyzed against high salt concentration to remove the inhibitor, and the dialysates from the test mixture and from a control without inhibitor were assayed for colicin content. Other controls determined that all inhibitor was removed by dialysis and that colicin was unaffected by the treatment. The results (Table 4) showed that in the control without inhibitor all colicin was adsorbed; 44% of the colicin remained unadsorbed in the presence of inhibitor. Thus, it appears that the inhibitor prevents adsorption of the colicin molecules to the sensitive cells.
Excretion of enterochelin and sensitivity to colicin B. Washed cells of exb mutants were absence of DHBA, the cells of GUA 13 aroC exb were somewhat less sensitive than those of the parent strain (Table 5) . Production or excretion of enterochelin is thus a major factor in the insensitivity mechanism. Since sensitivity of aroC ex b cells is not complete in the absence of DHBA, some other insensitivity mechanism may operate in these mutants. Leakiness of the aroC mutation or presence of trace amounts of 2,3-dihydroxybenzoic acid in the medium may also account for the residual insensitivity.
Colicin M is not inhibited by enterochelin. Many strains of E. coli colicinogenic for colicin B have recently have been found to produce colicin M (10) as well. Strain Cl 139 which was the source of colicin B used in the present work was found to produce two colicins corresponding to M and B by resistant mutant test. Crude colicin preparations have both colicin B and M activities which can be separated by sucrose density gradient centrifugation. After centrifugation at 100,000 x g for 20 h colicin M activity was found at the tube bottom, while B activity was in the top third of the tube.
The presence of colicin M raised the question of whether the findings on colicin action and inhibition are characteristic of colicin B, colicin M, or both. The indicator strain B#2 was found by stab test to be sensitive to the colicin B produced by R2.1 and insensitive to the colicin M produced by 32T19. Thus the results on the killing of B#2 cells and on the inhibition by enterochelin apply to colicin B. Crude colicin from strain Cl 139 does not affect [5-3H] uridine incorporation in strain ROW, which is insensitive to colicin B and sensitive to colicin M, suggesting that the biochemical mechanism of killing by colicin M is unlike that of colicin B. A supernatant fluid of an exb mutant failed to protect cells of strain ROW from the action of colicin M (Table 6) .
Purified lipopolysaccharide inhibits killing by colicin B. Early experiments (13) On the other hand, lipopolysaccharide extracted from several strains of E. coli, S. typhimurium, or S. anatum was highly inhibitory of colicin B action. The data for S. typhimurium strains are presented in Table 7 . In some preparations this inhibitory activity was unstable and disappeared after storage at 4 C. Lipopolysaccharide aggregates into a gel upon storage (26) , perhaps resulting in loss of inhibitory activity.
The inhibitory activity of lipopolysaccharide might be due to some contaminating substance. Lipopolysaccharide extracted from the S. typhimurium or from the LT 2 enb mutant GUS 7 which does not synthesize enterochelin was equally active in protecting sensitive cells from colicin ( Table 7 ), suggesting that inhibition is not attributable to enterochelin. These data also reveal that the inhibition of colicin B by lipopolysaccharide is more concentrationdependent than inhibition by enterochelin; this may reflect the state of aggregation of lipopolysaccharide. The inhibitory activity of lipopolysaccharide is not due to contamination by RNA, the major impurity in lipopolysaccharide, since ribonuclease treatment had no effect on this activity. DISCUSSION Identification of the colicin B inhibitor as enterochelin and several of its properties distinguish it from bacteriocin inhibitors that have been reported in other systems. A protein produced by Proteus mirabilis but not E. coli destroys colicin G with an exponential time course and is inactive on many colicins including B and I (28) . A temperature-sensitive protease excreted by a colicinogenic strain of Serratia marcescens destroys colicins E2 and K as well as the colicin produced by that strain (8) . Strains of Bacillus megaterium that produce megacin A, a phospholipase, excrete an inhibitor that is involved in immunity and functions by decreasing the turnover rate of the megacin (21) .
In contrast, enterochelin does not cause colicin destruction but functions by preventing adsorption of colicin B to sensitive cells. The role of enterochelin in iron transport is not yet known, but it is likely to involve some interaction between enterochelin and a specific envelope component, presumably protein. The inhibition of colicin B adsorption by enterochelin may also reflect an interaction with a cell surface protein, with the colicin molecule, or with both.
Colicin B is similar to colicins A, El, I, and K in the biochemical consequences they produce in sensitive cells: rapid and simultaneous cessation of nucleic acid and protein synthesis. These colicins apparently share a set of closely related biochemical targets, which are affected by mechanisms still under investigation. Colicin M does not affect cells in this manner, nor is its lethal effect inhibited by enterochelin. Since colicin M is readily sedimentable it may be related to the incompleted phage particles frequently encountered in strains of bacteria (3) .
The colicin inhibitory activity of lipopolysaccharide is independent of the presence of enterochelin and demonstrates greater concentration dependence, possibly reflecting the state of lipopolysaccharide aggregation. Several colicins are found associated with lipopolysaccharide when purified from culture fluids of colicinogenic cells (25) , and lipopolysaccharide inhibits killing by colicin E2 (5). These findings and the inhibition of colicin B may reflect a nonspecific affinity of lipopolysaccharide for certain classes of proteins. The weight of evidence indicates no relationship between lipopolysaccharide and the sensitive receptor, which for colicin E3 (27) and K (31) appears to be a protein from the
